Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778758 | 0.89 | CRBN (0.66) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL5496321 | 0.87 | CRBN (0.76) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL23812319 | 0.80 | CRBN (0.69) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL17169744 | 0.80 | CRBN (1.00) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL29923298 | 0.80 | CRBN (1.00) | CRBNDDB1IKZF3BRD4 | |
| Hydrochloric Acid SCHEMBL19359358 | 0.79 | CRBN (0.97) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL4778728 | 0.78 | CRBN (0.74) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20811963 | 0.78 | CRBN (0.74) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL26646479 | 0.78 | CRBN (0.77) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20812494 | 0.77 | CRBN (0.67) | CRBNDDB1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007505922-A | — | — | 2007-03-15 | — | — | JP | claimed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | claimed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | claimed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | claimed |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | P2D, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8853253-B2 | Thalidomide analogs | P2D, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8546430-B2 | Thalidomide analogs | P2D, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130035363-A1 | Thalidomide Analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2013-02-07 | — | — | US | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| CN-1867331-B | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2010-05-26 | — | — | CN | disclosed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035363-A1 | Thalidomide Analogs | TNF, TNFRSF1A, TNFRSF9 | CRBN 241/4885DDB1 919/4885IKZF3 949/4885 |
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885IKZF3 854/4885 |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, TNFRSF9 | CRBN 241/4885DDB1 919/4885IKZF3 949/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885IKZF3 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.